1043-P: Screening for Presence of High-Risk Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) In the U.S. Primary Care Is Cost Effective

Introduction Gilead Sciences, Inc., Bainan Biotech, AbbVie Inc., Bristol-Myers Squibb Company, Abbott, Novo Nordisk, Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Siemens Healthcare Diagnostics, Intercept Pharmaceuticals, Inc. J.M. Paik: None. L. Henry: None. M. Stepanova: None. F. Nader: None.